Among C9orf72 carriers over the age of 45, for example, unpublished data from the Pre-Symptomatic Familial ALS (Pre-fALS) study suggest that the annual rate of phenoconversion is 3%–4%. Here, C9orf72 is linked to amyotrophic lateral sclerosis.